3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
6
Leukemia, Myeloid, Acute
4
Uveal Melanoma
2
Lymphoma
2
Leukemia
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Meningeal Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia, Myeloid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Kidney Diseases
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Melphalan
3
pembrolizumab
2
obinutuzumab
2
blinatumomab
2
Rituximab
2
Radiotherapy
2
Lenalidomide
2
Capecitabine
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
sacituzumab govitecan
1
palbociclib
1
nilotinib
1
isatuximab
1
avelumab
1
atezolizumab
1
acalabrutinib
1
Whole-Body Irradiation
1
Trastuzumab
1
Sirolimus
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Interleukin-2
×
90 days
×
Clear all
No trials found.